Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
858 Therapeutics’ $60 Million Series A Financing
ADARx’s $75 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One Capital Management on the deal. ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion...
Stablix Therapeutics’ $63 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Versant Ventures and NEA on the deal. Stablix Therapeutics announced a $63 million Series A financing. The funding round was...



























